- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
March 26, 2024Ronald Schutz, Brendan Johnson Named to Forbes Top 200 Lawyers in the United States
-
March 21, 2024Robins Kaplan Firm Members Appointed to Law360 Editorial Boards
-
March 20, 2024Brandon Vaughn Inducted into The International Society of Barristers
-
April 5, 2024Mass Torts Made Perfect
-
April 17, 2024American Antitrust Institute Virtual CLE Lunch & Learn
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
March 2024Do We Have to Share That Information? Attorney-Client Privilege in the Multi-Entity Context
-
March 2024Sellers of a Business: Know Thyself.
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Cumberland Pharma., Inc. v. Mylan Institutional LLC
January 07, 2013
Drug Product and Patent(s)-in-Suit: Acetadote® (N-acetylcysteine); U.S. Pat. No. 8,148,356 (“the ’356 patent”)
Nature of the Case and Issue(s) Presented: The issues presented concern Mylan’s inequitable conduct counterclaim and affirmative defense. In particular, Mylan alleged that the inventor of the ’356 patent failed to disclose certain references to the USPTO, failed to disclose communications from the FDA regarding the removal of EDTA in the formulation of the covered product, and made misrepresentations regarding the then-marketed Acetadote formulation as compared to the claimed formulation.
Cumberland sought to dismiss the counterclaim and affirmative defense on three grounds: (i) Mylan failed to alleged sufficient facts to demonstrate why the withheld information would have had any effect on whether the ’356 patent issued; (ii) the purportedly withheld information was cumulative of art already before the USPTO Examiner; and (iii) Mylan failed to specifically identify claims and/or limitations that would be materially affected by the withheld information.
Mylan argued that it sufficiently plead facts to support why the withheld information would have affected the issuance of the ’356 patent as the information would have rendered the asserted claims obvious and/or anticipated. Mylan further argued that the allegations, taken as true, provide a basis to infer the requisite intent for an inequitable conduct claim. Finally, Mylan argued that the withheld information was not cumulative as it alleged that the information would have changed the examiner’s decision regarding the patentability of the claims of the ’356 patent. Relying on the Federal Circuit’s decision in Exergen Corp. v. Wal-Mart Stores, Inc., the district court denied the majority of Cumberland’s motion.
Why Mylan Prevailed: Mylan alleged that the inventor of the ’356 patent knew of several FDA-issued references that were material to the patentability of the claims of the ’356 patent. The court did not require that Mylan specify which claims the references would be material to; it found it sufficient that Mylan identified particular portions of the references that allegedly taught various limitations found in the claims of the ’356 patent. The court found that Mylan’s allegations of what information should have been presented to the examiner and how that information would have affected patentability were sufficient to demonstrate that the references were not cumulative.
Likewise, the court found that Mylan’s allegations regarding the inventor’s alleged misleading statements to the PTO were sufficient because the allegations identified which statements were false and/or misleading and the information upon which Mylan asserts demonstrates that the inventor knew these particular statements were false and/or misleading. Mylan was not required to identify particular claims or limitations in the patent with respect to the alleged false statements.
The district court, however, did grant Cumberland’s motion regarding allegations that it failed to disclose prior art regarding pharmacokinetics of acetylcysteine. Mylan failed to set forth allegations demonstrating why these prior art references were related to the ’356 patent. The claims of the ’356 patent did not contain a specific limitation regarding pharmacokinetics such that the court was not able to infer the materiality of the withheld information.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.